|
Age at enrollment (years)
|
12.0 (7.0 – 15.0)
|
|
Female
|
4,760 (71%)
|
|
White Race
|
5,432 (81%)
|
|
Private health insurance
|
4,515 (67%)
|
|
Disease duration (years)
|
2.5 (0.4 – 6.1)
|
|
ILAR category:
|
|
Oligoarthritis, persistent
|
1,634 (24%)
|
|
Oligoarthritis, extended
|
519 (8%)
|
|
Polyarthritis, RF-
|
2,184 (33%)
|
|
Polyarthritis, RF+
|
472 (7%)
|
|
Psoriatic arthritis
|
490 (7%)
|
|
Enthesitis related arthritis
|
687 (10%)
|
|
Systemic arthritis
|
571 (9%)
|
|
Undifferentiated arthritis
|
147 (2%)
|
|
ANA+
|
3,004 (45%)
|
|
RF+
|
556 (8%)
|
|
CCP+
|
447 (7%)
|
|
HLA-B27+
|
545 (8%)
|
|
Polyarthritis course
|
4,269 (64%)
|
|
Uveitis, ever
|
721 (11%)
|
|
Number of active joints
|
1 (0 – 3)
|
|
Physician global assessment
|
1 (0 – 3)
|
|
Active enthesitis
|
469 (7%)
|
|
Clinically active sacroiliitis
|
237 (4%)
|
